Alessandra Carobbio

Nov 5, 2024 | nature.com | Tiziano Barbui |Alessandra Carobbio |Alessandro Vannucchi |Paola Guglielmelli |Alessandro Rambaldi |Naseema Gangat

AbstractWe analyzed the neutrophil-to-lymphocyte ratio (NLR) in 1508 patients with PV and found that those with an NLR ≥ 5 were generally older, had a longer disease history, and had higher cardiovascular risk factors, more arterial thrombosis, and more aggressive blood counts, indicating a more proliferative disease.

Oct 24, 2024 | nature.com | Tiziano Barbui |Alessandra Carobbio |Valerio De Stefano |Alessandro Rambaldi |Ayalew Tefferi

AbstractThis viewpoint summarizes findings from analyses of large personal patient databases of myeloproliferative neoplasms (MPNs) to assess the impact of thrombosis on mortality, disease progression, and second cancers (SC). Despite advances, the current incidence of arterial and venous thrombosis remains a challenge.

Oct 7, 2024 | onlinelibrary.wiley.com | Tiziano Barbui |Alessandra Carobbio |Paola Guglielmelli |Arianna Ghirardi

CONFLICT OF INTEREST STATEMENT No conflicts of interest were declared. Supporting Information Filename Description bjh19813-sup-0001-TableS1.docxWord 2007 document , 27.8 KB Table S1. REFERENCES 1, , , , , , et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140: 1200–1228. 2, , , , , , et al.

Apr 21, 2024 | nature.com | Alessandra Carobbio |Paola Guglielmelli |Valerio De Stefano |Ayalew Tefferi

TO THE EDITOR:Over the past decade, observational and population-based studies have documented an excess of solid tumors and lymphomas in patients with myeloproliferative neoplasms (MPN), including polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF), but the causes of this excess remain elusive [1,2,3].

Dec 14, 2023 | nature.com | Tiziano Barbui |Alessandra Carobbio |Naseema Gangat |Alessandro Vannucchi |Ayalew Tefferi

AbstractWe applied a parametric Markov five-state model, on a well-characterized international cohort of 1,545 patients with polycythemia vera (PV; median age 61 years; females 51%), in order to examine the impact of incident thrombosis on the trajectory of death or disease progression. At a median follow-up of 6.9 years, 347 (23%) deaths, 50 (3%) blast phase (BP), and 138 (9%) fibrotic (post-PV MF) transformations were recorded.